Stock Analysis on Net
Stock Analysis on Net

Allergan PLC (NYSE:AGN)

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Allergan PLC, consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

Microsoft Excel
Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Accounts payable and accrued expenses 5,289,500 6,348,700 5,692,200 4,995,300 4,634,400 4,787,200 4,695,600 4,683,800 5,072,300 5,541,400 4,541,700 4,684,600 4,795,400 5,019,000 5,425,400 4,490,100 4,701,100 4,349,500 4,513,500 5,945,000 5,820,100
Income taxes payable 73,400 65,100 88,900 91,000 126,900 72,400 184,700 93,000 117,500 74,900 221,100 158,700 69,800 57,800 784,600 92,600 68,500 54,200 84,700 70,400 101,600
Current portion of long-term debt 1,950,700 4,532,500 3,739,200 3,094,200 3,971,800 868,300 1,351,600 1,348,500 626,200 4,231,800 3,797,000 3,795,000 5,526,400 2,797,900 1,591,800 2,506,600 4,015,700 2,432,800 2,035,400 1,550,900 1,624,100
Current portion of lease liability, operating 119,800 124,400 118,400 123,200 116,100 — — — — — — — — — — — — — — — —
Deferred revenue — — — — — — — — — — — — — — — — — — 32,900 25,700 27,100
Current liabilities held for sale — — — — — — — — — — — — — — 223,700 1,778,100 1,410,200 1,491,800 1,449,500 — 17,400
Deferred tax liabilities — — — — — — — — — — — — — — — — — — 17,000 57,500 65,200
Current liabilities 7,433,400 11,070,700 9,638,700 8,303,700 8,849,200 5,727,900 6,231,900 6,125,300 5,816,000 9,848,100 8,559,800 8,638,300 10,391,600 7,874,700 8,025,500 8,867,400 10,195,500 8,328,300 8,133,000 7,649,500 7,655,500
Long-term debt, excluding current portion 17,599,000 18,116,500 18,786,000 19,609,300 19,554,100 22,929,400 22,231,800 24,002,000 25,936,400 25,843,500 26,539,100 26,443,300 26,223,000 29,970,800 31,178,200 37,075,100 38,551,800 40,293,400 40,648,100 41,319,400 42,700,500
Lease liability, operating, excluding current portion 438,300 446,100 437,400 414,800 415,200 — — — — — — — — — — — — — — — —
Other long-term liabilities 787,400 800,900 810,900 821,400 804,400 882,000 752,100 753,400 826,800 886,900 1,007,000 1,038,300 1,060,500 1,085,000 1,022,700 1,039,600 1,024,000 1,262,000 1,161,900 1,223,900 1,271,600
Long-term liabilities held for sale — — — — — — — — — — — — — — 23,800 476,500 512,400 580,100 639,900 — —
Other taxes payable 1,690,400 1,704,800 1,718,400 1,667,000 1,618,200 1,615,500 1,580,500 1,576,600 1,555,700 1,573,900 911,400 896,100 914,500 886,200 815,600 743,000 777,400 801,900 760,800 907,700 984,100
Deferred tax liabilities 2,456,200 4,363,700 4,519,300 4,968,400 5,235,600 5,501,800 5,225,300 5,137,500 5,540,400 6,352,400 10,802,000 12,486,000 13,048,500 12,969,100 12,811,500 7,776,700 7,563,900 7,985,700 13,992,500 15,236,100 15,439,500
Long-term liabilities 22,971,300 25,432,000 26,272,000 27,480,900 27,627,500 30,928,700 29,789,700 31,469,500 33,859,300 34,656,700 39,259,500 40,863,700 41,246,500 44,911,100 45,851,800 47,110,900 48,429,500 50,923,100 57,203,200 58,687,100 60,395,700
Total liabilities 30,404,700 36,502,700 35,910,700 35,784,600 36,476,700 36,656,600 36,021,600 37,594,800 39,675,300 44,504,800 47,819,300 49,502,000 51,638,100 52,785,800 53,877,300 55,978,300 58,625,000 59,251,400 65,336,200 66,336,600 68,051,200
Preferred shares, $0.0001 par value per share — — — — — — — — — 4,929,700 4,929,700 4,929,700 4,929,700 4,929,700 4,929,700 4,929,700 4,929,700 4,929,700 4,929,700 4,929,700 4,929,700
Ordinary shares; $0.0001 par value per share — — — — — — — — — — — — — — — — — — — — —
Treasury shares, at cost — — — — — — — — — — — — — — (400,000) — — — — — —
Additional paid-in capital 56,036,200 55,974,900 55,882,400 55,811,900 55,742,800 56,510,000 57,203,000 57,567,700 57,486,900 54,013,500 54,381,300 54,267,800 54,107,100 53,958,900 66,184,200 68,769,000 68,658,300 68,508,300 68,241,400 68,103,100 67,969,300
Retained earnings (accumulated deficit) 882,500 991,500 1,551,700 2,581,100 4,582,800 7,258,900 11,800,600 12,082,900 12,799,500 12,957,200 10,137,200 14,397,900 15,429,900 18,342,500 18,412,700 3,262,300 3,833,600 3,647,500 4,347,900 (953,300) (710,900)
Accumulated other comprehensive income (loss) 1,079,000 1,207,200 1,041,100 1,281,700 1,216,400 1,345,200 1,504,200 1,592,900 2,041,500 1,920,700 1,711,200 1,625,000 721,700 (1,038,400) 599,300 (317,100) 28,400 (494,100) (45,300) (10,400) (783,300)
Shareholders’ equity 57,997,700 58,173,600 58,475,200 59,674,700 61,542,000 65,114,100 70,507,800 71,243,500 72,327,900 73,821,100 71,159,400 75,220,400 75,188,400 76,192,700 89,725,900 76,643,900 77,450,000 76,591,400 77,473,700 72,069,100 71,404,800
Noncontrolling interest 23,800 22,800 23,000 21,400 17,600 16,900 13,100 20,500 18,100 16,000 14,100 12,400 10,400 7,800 4,500 (3,100) (1,300) (2,100) 6,400 5,400 4,700
Total equity 58,021,500 58,196,400 58,498,200 59,696,100 61,559,600 65,131,000 70,520,900 71,264,000 72,346,000 73,837,100 71,173,500 75,232,800 75,198,800 76,200,500 89,730,400 76,640,800 77,448,700 76,589,300 77,480,100 72,074,500 71,409,500
Total liabilities and equity 88,426,200 94,699,100 94,408,900 95,480,700 98,036,300 101,787,600 106,542,500 108,858,800 112,021,300 118,341,900 118,992,800 124,734,800 126,836,900 128,986,300 143,607,700 132,619,100 136,073,700 135,840,700 142,816,300 138,411,100 139,460,700

Based on: 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Allergan PLC current liabilities increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Allergan PLC long-term liabilities decreased from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Allergan PLC total liabilities increased from Q3 2019 to Q4 2019 but then decreased significantly from Q4 2019 to Q1 2020.
Shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Allergan PLC shareholders’ equity decreased from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.